183 related articles for article (PubMed ID: 1350073)
1. Dopamine agonists used as monotherapy in de novo PD patients: comparisons with selegiline.
Lieberman A
Neurology; 1992 Apr; 42(4 Suppl 4):37-40; discussion 41-8. PubMed ID: 1350073
[TBL] [Abstract][Full Text] [Related]
2. Controversies in the therapy of Parkinson's disease.
Fahn S
Adv Neurol; 1996; 69():477-86. PubMed ID: 8615168
[TBL] [Abstract][Full Text] [Related]
3. Recent advances in Parkinson's disease therapy: use of monoamine oxidase inhibitors.
Henchcliffe C; Schumacher HC; Burgut FT
Expert Rev Neurother; 2005 Nov; 5(6):811-21. PubMed ID: 16274338
[TBL] [Abstract][Full Text] [Related]
4. Treatment of Parkinson's disease.
Lieberman A
Curr Opin Neurol Neurosurg; 1993 Jun; 6(3):339-43. PubMed ID: 8507903
[TBL] [Abstract][Full Text] [Related]
5. [Optimization of the treatment of Parkinson's disease using dopamine agonists].
Rinne UK
Arch Neurobiol (Madr); 1991; 54(6):282-7. PubMed ID: 1687430
[No Abstract] [Full Text] [Related]
6. Monamine oxidase inhibitors: current and emerging agents for Parkinson disease.
Fernandez HH; Chen JJ
Clin Neuropharmacol; 2007; 30(3):150-68. PubMed ID: 17545750
[TBL] [Abstract][Full Text] [Related]
7. Initiating treatment of Parkinson's disease.
Koller WC
Neurology; 1992 Jan; 42(1 Suppl 1):33-8; discussion 57-60. PubMed ID: 1347909
[TBL] [Abstract][Full Text] [Related]
8. [Rasagiline in daily clinical use. Results of a treatment study of Parkinson patients with a combination treatment].
Jost WH; Klasser M; Reichmann H
Fortschr Neurol Psychiatr; 2008 Oct; 76(10):594-9. PubMed ID: 18833504
[TBL] [Abstract][Full Text] [Related]
9. Selegiline slows the progression of the symptoms of Parkinson disease.
Pålhagen S; Heinonen E; Hägglund J; Kaugesaar T; Mäki-Ikola O; Palm R;
Neurology; 2006 Apr; 66(8):1200-6. PubMed ID: 16540603
[TBL] [Abstract][Full Text] [Related]
10. New concepts in the treatment of Parkinson's disease.
Ahlskog JE; Wilkinson JM
Am Fam Physician; 1990 Feb; 41(2):574-84. PubMed ID: 1967895
[TBL] [Abstract][Full Text] [Related]
11. Selegiline: a second look. Six years later: too risky in Parkinson's disease.
Prescrire Int; 2002 Aug; 11(60):108-11. PubMed ID: 12199263
[TBL] [Abstract][Full Text] [Related]
12. The effects of early selegiline therapy on long-term levodopa treatment and parkinsonian disability: an interim analysis of a Norwegian--Danish 5-year study. Norwegian-Danish Study Group.
Larsen JP; Boas J
Mov Disord; 1997 Mar; 12(2):175-82. PubMed ID: 9087975
[TBL] [Abstract][Full Text] [Related]
13. Parkinson's disease therapy: treatment of early and late disease.
Jankovic J
Chin Med J (Engl); 2001 Mar; 114(3):227-34. PubMed ID: 11780303
[TBL] [Abstract][Full Text] [Related]
14. Moderate Parkinson's disease. Strategies for maximizing treatment.
Silverstein PM
Postgrad Med; 1996 Jan; 99(1):52-4, 61-3, 67-8, passim. PubMed ID: 8539210
[TBL] [Abstract][Full Text] [Related]
15. Parkinson's disease. Diagnosis and the initiation of therapy.
Bhat V; Weiner WJ
Minerva Med; 2005 Jun; 96(3):145-54. PubMed ID: 16175158
[TBL] [Abstract][Full Text] [Related]
16. Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease.
Chen JJ; Swope DM; Dashtipour K
Clin Ther; 2007 Sep; 29(9):1825-49. PubMed ID: 18035186
[TBL] [Abstract][Full Text] [Related]
17. Relating mode of action to clinical practice: dopaminergic agents in Parkinson's disease.
Riederer P; Gerlach M; Müller T; Reichmann H
Parkinsonism Relat Disord; 2007 Dec; 13(8):466-79. PubMed ID: 17919963
[TBL] [Abstract][Full Text] [Related]
18. Long-term experience with selegiline and levodopa in Parkinson's disease.
Lieberman A
Neurology; 1992 Apr; 42(4 Suppl 4):32-6; discussion 41-8. PubMed ID: 1584430
[TBL] [Abstract][Full Text] [Related]
19. Monoamine oxidase-B inhibition in the treatment of Parkinson's disease.
Fernandez HH; Chen JJ
Pharmacotherapy; 2007 Dec; 27(12 Pt 2):174S-185S. PubMed ID: 18041937
[TBL] [Abstract][Full Text] [Related]
20. Recent advances in the clinical pharmacology of Parkinson's disease.
Montastruc JL
Therapie; 1991; 46(4):293-303. PubMed ID: 1683024
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
